Altre lingue Capricor Therapeutics, Inc.

Azioni

CAPR

US14070B3096

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 03/05/2024			Variaz. 5gg	Var. 1 gen.
5,47 ^USD	+4,39%		+1,11%	+11,86%

29/04	Transcript : Capricor Therapeutics, Inc. - Special Call
24/04	Capricor Therapeutics ottiene un altro incontro di tipo B con la FDA per il farmaco sperimentale per la distrofia muscolare di Duchenne	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	24/04
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24/04
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24/04
Capricor Therapeutics to Present at Upcoming Investor Conferences	21/03
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	06/03
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06/03
Capricor: Q4 Earnings Snapshot	29/02
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	29/02
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Sector Update: Health Care Stocks Ease Late Afternoon	27/02
Sector Update: Health Care Stocks Decline Tuesday Afternoon	27/02
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise	27/02
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy	27/02
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29	22/02
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization	20/02
Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization	20/02
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine	24/01
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2	24/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Capricor Therapeutics, Inc.

Azioni

CAPR

US14070B3096

Altre lingue

Filtri